Dr. Nayyer Iqbal MD

Nayyer Iqbal, MBBS, M.Phil, FRCP (Edinburgh), FRCP (Ireland), FRCR (UK) is a staff medical oncologist at the Saskatchewan Cancer Agency (SCA), Saskatoon Cancer Centre and Clinical Associate Professor at the University of Saskatchewan. He is also Adjunct Professor in the Division of Oncology, College of Graduate and Postdoctoral Studies and Research, University of Saskatchewan.

 

Dr. Iqbal graduated from the Dow Medical College, University of Karachi, Pakistan. He initially did his training in pathology and completed M. Phil in pathology from Jinnah Postgraduate Medical Centre, University of Karachi, Pakistan. He carried out a prospective research on Hepatocellular Carcinoma and the title of his THESIS was “Frequency of Hepatitis B Surface Antigen, Hepatitis B Core Antigen, Alpha-Fetoprotein and Alpha-l-Antitrypsin in tissue blocks by PAP Technique”. He received the award of W.H.O. International Fellow. His interest in Oncology during his research led him to move to United Kingdom. He first completed Internal Medicine Training and passed MRCP both from UK and Ireland. Then he completed 5 years of Oncology Training in UK leading to CCST (Certificate of Completion of Specialist Training). He has completed Fellowship in internal medicine and Clinical Oncology.

 

He worked as consultant Oncologist for many years in Tertiary Cancer Centre in UK until he moved to Saskatoon in 2010. He has worked as Director of Medical Oncology for 8 years at Saskatoon Cancer Centre and implemented transformational changes. His areas of expertise are Genitourinary malignancy and breast cancer. He is Lead in medical Oncology at Saskatoon Cancer Center for GU Guideline development since 2020, Lead in medical Oncology at Saskatoon Cancer Center for clinical trials in GU (2013 to Present) & Breast since 2019.

 

He has been principal investigator of many international and national clinical trials. 2020 CCTG Phase III Team Award for Intergroup-Lead trials has been awarded to Saskatoon Cancer Centre MAC.21 trial Team based on the center’s accrual metrics, local activation and compliance metrics. Dr. Iqbal is the Principal Investigator for this trial. His research has been published in many peer-reviewed journals. Dr Iqbal has many publications and he is also writer of chapter on breast cancer in “Practical Clinical Oncology” published by Cambridge University Press; First Edition in 2008, Second edition in 2015. He is also the member of Canadian Clinical Trials Group of Genitourinary group and breast group. Dr. Iqbal is passionate in teaching and mentoring undergraduates and Residents both in the clinics and interactive one to one teaching sessions and wishes to work with University of Saskatchewan to include solid tumors as part of undergraduate curriculum because of extensive research opportunity in this area of medicine.

 

Dr. Iqbal is the co-author of the Late-Breaking Abstract presented in SABCS, San Antonio, Texas, December 8-12, 2020 on “Tucatinib on Health-Related Quality of Life in Patients with HER2+ Metastatic Breast Cancer with Active Brain Metastases”. He is also the co-author of “Quality of Life Is Preserved in Previously Treated HER2+ Metastatic Breast Cancer Patients with Tucatinib vs Placebo Added to Trastuzumab and Capecitabine (HER2CLIMB) which is submitted to Annals of Oncology, December 2020. He is also the co-author of “Cabazitaxel versus abiraterone or enzalutamide in poor prognosis metastatic castration-resistant prostate cancer: a multicenter, randomized, open-label, phase 2 trial”, submitted to Lancet Oncology, November 2020. During recent COVID-19 Pandemic, he also contributed in “Prioritizing systemic therapies for genitourinary malignancies: Canadian recommendations during the COVID-19 pandemic” published in Can Urol Assoc J 2020 May 5;14(5): E154-E158. Epub 2020 Apr 5.